Introduction {#Sec1}
============

Over 25 clinical trials for sepsis have failed \[[@CR1],[@CR2]\], suggesting that our current understanding of its pathogenesis is incomplete. Deaths occur days to weeks after diagnosis and have been attributed to one of two phenomena \[[@CR3]\]. First, a subset of patients succumbs to an overwhelming acute inflammatory response driven by the innate immune system, leading to death within days of the initial infection. However, most patients survive this phase and the repeated failure of anti-inflammatory therapies for sepsis (for example, anti-tumor necrosis factor antibodies \[[@CR4]\], high-dose corticosteroids \[[@CR5]\]) indicates that inflammation *per se* is unlikely to be a major cause of death. Most sepsis deaths occur later and have been associated with dysfunction of the innate and adaptive immune systems \[[@CR6]\], characterized by decreased cytokine production and lymphocyte apoptosis \[[@CR7]\]. These mechanisms have been postulated to cause immunosuppression \[[@CR3],[@CR8],[@CR9]\], predisposing patients to fatal nosocomial infections. Based on this hypothesis, immunoadjuvant therapy to boost the immune system has been proposed recently as a therapeutic approach.

The argument against nosocomial infection {#Sec2}
=========================================

The notion of death due to nosocomial infection is at odds with our clinical experience, in which patients with sepsis die despite broad-spectrum antibiotics and negative microbial cultures. Indeed, two studies often cited as evidence for this theory are open to alternative interpretations. The first study reported a high (\~80 %) rate of infected foci in those patients dying from sepsis \[[@CR10]\]. Yet it was unclear whether culture data reflected only postmortem or perimortem cultures, or incorporated laboratory results taken earlier during hospitalization -- a period in which positive cultures would be expected. The second study did not report the incidence of positive cultures in patients who died from sepsis, a critical statistic for determining the contribution of nosocomial infection to mortality \[[@CR1]\]. This study described three phases of mortality, divided into deaths occurring within hospital days 0 to 5 (phase I), days 6 to 15 (phase II) and days 16 to 150 (phase III). Despite the fact that phase III included the largest number of days by far, the mortality rate was highest in phase I, arguing against late nosocomial infection being the main cause of death.

A recent retrospective analysis in our own center has provided further evidence against this theory. We considered all patients admitted to the ICU who were screened for a sepsis study of heparin (Heparin Anticoagulation to Improve Outcomes in Septic Shock; ClinicalTrials.gov NCT 1648036) and subsequently died. From these patients, we selected those who actually had sepsis and looked for evidence of a secondary nosocomial infection, defined as a detected new microbial isolate prior to death. Of 26 consecutive patients dying of septic shock in a mixed medical--surgical ICU, only three (14 %) patients had evidence of a new infection at the time of death (Table [1](#Tab1){ref-type="table"}). While our study is not definitive, taken together with other results, the theory that nosocomial infection is the predominant cause of death from sepsis seems tenuous.Table 1**Lack of evidence of nosocomial infection in a retrospective cohort of patients dying of sepsisAge range (years)Source of infectionSOFA scoreICU LOS (days)Days from diagnosis to deathDays from final culture to deathFinal culture resultCause of deathEvidence of nosocomial infection**70 to 79Lung1216131No growthCancerNo nosocomial infection60 to 69Skin and soft tissue955555No growthCHFNo nosocomial infection80 to 89Genitourinary121142No growthCHFNo nosocomial infection70 to 79Bloodstream1517172Original organismIE/sepsisNo nosocomial infection80 to 89Lung185473\<1Original organismIschemic bowelNo nosocomial infection40 to 49Intra-abdominal12141414No growthLiver failureNo nosocomial infection80 to 89Lung1112101No growthMINo nosocomial infection70 to 79Lung10531Original organismMINo nosocomial infection40 to 49Bloodstream211441No growthMOFNo nosocomial infection50 to 59Bloodstream1516333No growthMOFNo nosocomial infection40 to 49Intra-abdominal17451No growthMOFNo nosocomial infection70 to 79Intra-abdominal1642433No growthMOFNo nosocomial infection60 to 69Lung919182No growthMOFNo nosocomial infection50 to 59Skin and soft tissue1310111No growthMOFNo nosocomial infection60 to 69Skin and soft tissue1476572No growthMOFNo nosocomial infection\<30Skin and soft tissue148685\<1No growthMOFNo nosocomial infection80 to 89Genitourinary16111Original organismMOFNo nosocomial infection70 to 79Lung434223No growthTumor lysisNo nosocomial infection40 to 49Intra-abdominal746741New organismMOFNosocomial infection70 to 79Intra-abdominal5661New organismMOFNosocomial infection\<30Intra-abdominal123737\<1New organismPancreatitisNosocomial infection60 to 69Intra-abdominal5173New organismMOFIndeterminate50 to 59Skin and soft tissue1237374No growthMOFIndeterminate40 to 49Lung1668506No growthMOFIndeterminate70 to 79Lung13171713Original organismMOFIndeterminate70 to 79Intra-abdominal14313\<1No growthSepsisIndeterminateThe initial antibiotic therapy was checked against culture and sensitivity results to record the appropriateness of antibiotic therapy for the initial isolate. Results of the final culture before death and the time from that culture until death are indicated (\<1 means the same day as death). CHF, congestive heart failure; IE, infective endocarditis; LOS, length of stay; MI, myocardial infarction; MOF, multiorgan failure; SOFA, Sequential Organ Failure Assessment.

If not infection, what else? {#Sec3}
============================

Mitochondrial dysfunction {#Sec4}
-------------------------

There is substantial evidence for mitochondrial dysfunction in sepsis \[[@CR11]\]. The theory is that if perfusion and oxygen content are adequate but organ dysfunction still exists, the cells must be unable to use oxygen. Several factors, including reactive oxygen species, hormonal deficiencies, and the impact of systemic inflammation on mitochondrial gene transcription, are thought to contribute \[[@CR11],[@CR12]\]. Furthermore, leukocytes from septic patients have been shown to possess abnormal oxygen metabolism \[[@CR13]\], and mitochondrial dysfunction has been associated with poor outcomes in septic shock \[[@CR14]\]. While trials of antioxidant therapy have been unsuccessful (reviewed in \[[@CR2]\]), further trials are needed to determine the validity of this approach.

Microvascular leak {#Sec5}
------------------

Another theory for death from sepsis implicates systemic vascular leak (Figure [1](#Fig1){ref-type="fig"}) \[[@CR15],[@CR16]\]. Loss of endothelial barrier integrity leads to tissue edema, hypoperfusion, and organ dysfunction. These features are characteristic of human sepsis but until recently were absent from animal models. Importantly, various lines of evidence for this theory exist. In mice, buttressing the endothelial barrier directly protected against death from sepsis \[[@CR17],[@CR18]\]. In humans, limiting fluids accelerated recovery in acute respiratory distress syndrome \[[@CR19]\], while a positive fluid balance was associated with worse outcome in sepsis \[[@CR20]\]; most recently, in a *post hoc* subgroup of the sickest sepsis patients, albumin therapy -- which would limit edema formation -- was also protective \[[@CR21]\].Figure 1**Evidence supporting nosocomial infection as the major cause of death in sepsis is weak.** Alternative hypotheses include the role of mitochondrial dysfunction as well as systemic microvascular leak (see text). ARDS, acute respiratory distress syndrome.

Conclusion {#Sec6}
==========

Sepsis has been termed a pharmaceutical 'graveyard' \[[@CR22]\] due to repeated failure of human clinical trials. Despite calls for a trial of immunoadjuvant therapy, the evidence supporting nosocomial infection as the main cause of death is weak. A small study of granulocyte--macrophage colony-stimulating factor in patients with severe sepsis/septic shock observed improvements in monocyte function but no significant change in a host of clinical parameters except for the duration of mechanical ventilation \[[@CR23]\]. Practically, if most patients who die from sepsis have sterile cultures, it is unlikely that boosting the immune system or adding additional antibiotics will improve outcomes. Further research into the contribution of nosocomial infection to sepsis mortality is thus necessary, as well as research into other potential contributors such as systemic microvascular leak.
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